Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: Out-patient treatment is a viable option

Bone Marrow Transplantation

Volumn 23, Issue 6, 1999, Pages 599-605

  Seropian, S ^a   Nadkarni, R ^a   Jillella, A P ^a   Salloum, E ^a   Burtness, B ^a   Hu, G L ^b   Zelterman, D ^b   Cooper, D L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YALE CANCER CENTER   (United States)

Author keywords

Autologous stem cell transplantation; Infection; Neutropenia

Indexed keywords

ACICLOVIR; AMPHOTERICIN; CARMUSTINE; CD34 ANTIGEN; CIPROFLOXACIN; CYTARABINE; ETOPOSIDE; FLUCONAZOLE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ARTICLE; BACTERIAL INFECTION; FEBRILE NEUTROPENIA; FEMALE; GRAM POSITIVE BACTERIUM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPES SIMPLEX; HODGKIN DISEASE; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEUTROPHIL; NONHODGKIN LYMPHOMA; NONHUMAN; ORAL DRUG ADMINISTRATION; OUTPATIENT CARE; PRIORITY JOURNAL;

EID: 0032981810     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701610     Document Type: Article

References (23)

1. Schmitz N, Linch D, Dreger P et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
2. Hartmann O, Le Corroler A, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. Ann Intern Med 1997; 126: 600-607.
3. Nosanchuk JD, Sepkowitz KA, Pearse RN et al. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukemia and lymphoma. Bone Marrow Transplant 1996; 18: 355-359.
4. Mossad SB, Longworth DL, Goormastic M et al. Early infectious complications in autologous bone marrow transplantation: a review of 219 patients. Bone Marrow Transplant 1996; 18: 265-271.
5. Kolbe K, Domkin D, Derigs HG et al. Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation. Bone Marrow Transplant 1997; 19: 143-147.
6. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
7. Colombat P, Biron P, Laporte J et al. Beam protocol and autologous bone marrow transplantation in first chemosensitive relapse of non-Hodgkin's lymphomas. Eur J Cancer 1990; 26: 858.
8. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. New Engl J Med 1993; 328: 1323-1332.
9. Bodey GP, Buckley M, Sathe YS et al. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1996; 64: 328-340.
10. Malik IA, Khan WA, Karim M et al. Feasibility of outpatient management of fever in cancer patients with low-risk neutropenia: results of a prospective randomized trial (see comments). Am J Med 1995; 98: 224-231.
11. Rubenstein EB, Rolston K, Benjamin RS et al. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer. Cancer 1993; 71: 3640-3646.
12. Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. The GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (see comments). Ann Intern Med 1991; 115: 7-12.
13. Bow EJ, Mandell LA, Louie TJ et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group (see comments). Ann Intern Med 1996; 125: 183-190.
14. Lew MA, Kehoe K, Ritz J et al. Ciprofloxacin vs trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: a randomized, controlled trial. J Clin Oncol 1995; 13: 239-250.
15. Bow EJ, Loewen R, Vaughan D. Reduced requirement for antibiotic therapy targeting gram-negative organisms in febrile, neutropenic patients with cancer who are receiving antibacterial chemoprophylaxis with oral quinolones. Clin Infect Dis 1995; 20: 907-912.
16. Cruciani M, Rampazzo R, Malena M et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis (see comments). Clin Infect Dis 1996; 23: 795-805.
17. Engels E, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998; 16: 1179-1187.
18. Carratala J, Fernandez-Sevilla A, Tubau F et al. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995; 20: 557-560; discussion 561-563.
19. Carratala J, Fernandez-Sevilla A, Tubau F et al. Emergence of fluoroquinolone-resistant Escherichia coli in fecal flora of cancer patients receiving norfloxacin prophylaxis. Antimicrob Agents Chemother 1996; 40: 503-505.
20. Cometta A, Calandra T, Bille J et al. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia (letter) (see comments). New Engl J Med 1994; 330: 1240-1241.
21. Kern WV, Andriof E, Oethinger M et al. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother 1994; 38: 681-687.
22. Ball P. Editorial response: is resistant Escherichia coli bacteremia an inevitable outcome for neutropenic patients receiving a fluoroquinolone as prophylaxis? Clin Infect Dis 1995; 20: 561-563.
23. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center 8-year study of 155 patients. Blood 1993; 81: 1137-1145.